



## COVID-19 Pathophysiology and Clinical Effects on Multiple Organ Systems: A Review

<sup>1\*</sup>Kinal Bhatt, MD, MPH., <sup>2</sup>Jonathan Quinonez, DO., <sup>3</sup>Abhinav Patel, MBBS., <sup>4</sup>Mehrie H. Patel, MBBS., <sup>5</sup>Abdifitah Mohamed, MBBS., <sup>6</sup>Muhammad Ali Aziz, MBBS., <sup>7</sup>Deepa Venkataramani, <sup>8</sup>Fatema Zohora, MBBS., <sup>9</sup>Namrata Hange, MBBS., MPH., <sup>10</sup>Dana Awad, <sup>11</sup>Isha Mehta, MD., <sup>12</sup>Paz Ines M. Domingo, MD., <sup>13</sup>Nadia Jamil., <sup>14</sup>Shravika Reddy Kandi, <sup>15</sup>Sindhu Thevuthasan., <sup>16</sup>Uzzam Ahmed Khawaja, <sup>17</sup>Dhanya Baskaran, MD., <sup>18</sup>LaShathan Banks DO, MS, <sup>18</sup>George Michel, MD., <sup>17</sup>Dr Marcos Sanchez-Gonzales, MD., PhD.

<sup>1</sup> Division of Clinical & Translational Research, Larkin Health System, South Miami, FL, USA

<sup>2</sup>The Haley Center, Winter Haven, FL, USA

<sup>3</sup>Terna Medical College, Navi Mumbai, India

<sup>4</sup>Pramukhswami Medical College, Gujarat, India

<sup>5</sup>Shendi University, Shendi, Sudan

<sup>6</sup>King Edward Medical University, Lahore, Pakistan

<sup>7</sup>Aureus University School of Medicine, Oranjestad, Aruba

<sup>8</sup>ZH Sikder Medical College, Dhaka, Bangladesh

<sup>9</sup>National University of Singapore, Singapore

<sup>10</sup>Damascus University, Damascus, Syria

<sup>11</sup>Windsor University School of Medicine, Cayon, St. Kitts

<sup>12</sup>University of the East Ramon Magsaysay Memorial Medical Center, Quezon City, Philippines

<sup>13</sup>Sargodha Medical College, Sargodha, Pakistan

<sup>14</sup>Malla Reddy Institute of Medical Sciences, Hyderabad, India

<sup>15</sup>Medical University of the America, Camps, St. Kitts & Nevis

<sup>16</sup>Jinnah Medical and Dental College, Abbottabad, Pakistan

<sup>17</sup>Division of Clinical & Translational Research, Larkin Health System, South Miami, FL, USA

<sup>18</sup>Larkin Community Hospital, South Miami, FL, USA

\*Corresponding Author: \*\*\*\*\*

### ABSTRACT

Patients with comorbidities including Hypertension (HTN), Diabetes Mellitus (DM), Chronic Obstructive Pulmonary Disease (COPD), Asthma, Obesity, Cardiovascular Disease (CVD), Chronic Kidney Disease (CKD), and those who are immunocompromised are prone to more severe complications of COVID-19 and a higher rate of hospitalizations. In the United States, around 94% of COVID-19 deaths had an average of 2.6 additional conditions or causes per death. In a summary report published by the Chinese Centre for Disease Control and Prevention of 72,314 cases, case-fatality rate was elevated among

Copyright © 2020. The Author(s). This is an open access preprint (not peer-reviewed) article under [Creative Commons Attribution-NonCommercial 4.0 International](https://creativecommons.org/licenses/by-nc/4.0/) license, which permits any non-commercial use, distribution, adaptation, and reproduction in any medium, as long as the original work is properly cited. **However, caution and responsibility are required when reusing as the articles on preprint server are not peer-reviewed.** Readers are advised to click on URL/doi link for the possible availability of an updated or peer-reviewed version.

### How to Cite:

Kinal Bhatt *et al.*, "COVID-19 Pathophysiology and Clinical Effects on Multiple Organ Systems: A Review". *AIJR Preprints*, 254, Version 1, 2020.

those with preexisting comorbid conditions—10.5% for cardiovascular disease, 7.3% for diabetes, 6.3% for chronic respiratory disease, 6.0% for HTN, and 5.6% for cancer. The COVID-19 pandemic continues to threaten people and healthcare systems globally and therefore the global economy. Currently, there is no cure or vaccine for COVID-19 and there is an urgent need to develop target therapies as we continue to learn more about this novel virus. Without therapeutic interventions, much of how we contain the viral spread is prevention through mitigation strategies (social distancing, face masks, supportive care). Early suspicion of COVID-19 symptoms with radiological and laboratory assessments may play a major role in preventing severity of the COVID-19. With this literature review we aim to provide review of pathophysiology of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and its clinical effects on multiple organ systems.

**Keywords:** COVID-19, Pathophysiology, Clinical Effects.

## 1 Introduction

In December 2019, cases of pneumonia of unknown etiology were detected in the city of Wuhan, China linked to people who had visited or worked at The Huanan (Southern China) Seafood Wholesale Market. Subsequently, these cases were attributed to a novel virus now known as SARS-CoV-2 [1]. SARS-CoV-2 is a highly pathogenic, virulent virus that belongs to the coronavirus family of enveloped, single-stranded RNA viruses, humans being primary host [2][3]. After the number of affected countries tripled, and the case burden of the SARS-CoV-2 increased thirteen-fold, the World Health Organization (WHO) declared the outbreak a pandemic on March 11, 2020 [4]. Patients infected with COVID-19 have reported a varied range of symptoms – from mild symptoms to severe illness, with symptoms appearing 2-14 days after being exposed to the virus. There are three major forms in which the disease manifests, a gradual mild illness that is dominated by symptoms related to upper respiratory tract; non-life-threatening pneumonia; and a severe pneumonia with acute respiratory distress syndrome (ARDS) that starts with mild symptoms for around a week and subsequently deteriorates into ARDS, sepsis, and multiple organ failure [3, 5]. According to the CDC, the most frequent clinical manifestations include cough, dyspnea, fever, and sore throat. Patients have also reported new loss of taste and smell in other cases. COVID-19 affects almost every organ system in the body; due to its nature of transmission, it affects the lung tissue more so than others due to extensive distribution of angiotensin-converting enzyme-2 (ACE2) receptors. This can cause damage in the cardiovascular, renal, liver, central nervous system, gastrointestinal, and ocular systems that requires careful management [6, 7].

Patients with comorbidities such as HTN, DM, COPD, Asthma, Obesity, CVD, CKD, and malignancies are prone to more severe complications of COVID-19 and a higher rate of hospitalizations [8]. In the United States, Around 94% of COVID-19 deaths had an average of 2.6 additional conditions or causes per death [9]. The current guidelines for minimizing the spread of COVID-19 involves the use of alcohol-based hand sanitizer [10, 11], thoroughly washing hands with soap and water, maintaining a distance of 1m-2m (3-6ft) with others, self-isolation of people who were exposed, or are experiencing symptoms, and practicing good respiratory hygiene[10]. Public masking has been widely accepted as one of the most important pillars of controlling the COVID-19 pandemic [12, 13]. Use of a face mask not only reduces the spread of the virus from infected patients to others, but it also lowers the exposure of the mask wearer to the inoculum, thereby possibly resulting in a lower severity of the disease [13]. Contact tracing, social distancing and ample testing have proven to be highly effective in reducing the transmission of the virus. [14]. Healthcare professionals involved in care for infected patients should make sure they are implementing proper contact and airborne precautions, which includes PPE such as N95 masks, eye protection, gowns, and gloves to prevent transmission of the virus. As of September 22, 2020, there is no definitive cure

for COVID-19. Treatment generally involves supportive care. There are 38 COVID-19 candidate vaccines in the clinical evaluation stage with 9 of them being in Phase III of clinical trials. WHO also reports that there are 149 candidate vaccines in the preclinical evaluation stage [15]. Multiple clinical trials are being undertaken to identify effectiveness of anti-virals, glucocorticoids, nutraceuticals, and supplements in treatment for COVID-19.

## 2 Epidemiology

The first case of COVID-19 was reported in Wuhan, China in early December 2019 [16]. The number of COVID-19 cases reported to the WHO has been increasing since then. A month later, on January 20th 2020, WHO reported that there was a total of 282 confirmed cases of COVID-19 in four countries including China (278 cases), Thailand (2 cases), Japan (1 case) and the Republic of Korea (1 case) [17]. During the initial stages of COVID-19 spread, most cases reported globally that were outside of China, and therefore attributed to travelers who were infected in China and then travelled outside the country [18]. The first case of human-to-human transmission of COVID-19 in the US was reported in Washington State on January 20th, 2020 in a patient who had returned from Wuhan, China after visiting his family [19]. The virus then rapidly spread throughout the country and the United States quickly became an epicenter with New York reporting the most cases (475,000 cases reported as of October 9, 2020) [20]. The first death in the US due to COVID19 was reported on April 13th, 2020 in Wisconsin, with New York reporting most deaths (32,859 death reported as of October 9, 2020) at later stages of the pandemic [20].

According to the WHO, by March 2020, during the initial stages of the pandemic, SARS-CoV-2 had spread to over 100 countries, with over 100,000 infections and over 3,500 deaths and an estimated case fatality rate was 0.9%-3% [21]. As the pandemic progressed, according to the data reported by WHO on September 13<sup>th</sup>, there are a total of 28,637,952 confirmed cases globally, with a total of 917,417 number of deaths across 216 countries [22]. With 51% of the total cases reported in the Americas, it has the highest number of cases among the WHO regions. At the beginning of the outbreak the infection followed exponential growth where the infection cases doubled in size every 7.4 days. The basic reproduction number was from 2.24 to 3.58, which is higher than SARS [23]. All age groups are likely to be affected by COVID-19 with majority of patients between 36 to 65 years of age [24].

In a summary report published by the Chinese Centre for Disease Control and Prevention, of 72,314 cases, most patients affected were between the ages 30-70 (87%) followed by patients of 20-29 years of age (8%) and patients greater than 80 years of age (3%). The least affected age groups were between 10 to 19 years of age (1%). The cases were identified as mild in 81%, severe in 14% and critical in 5% of patients. The case fatality rate was highest in critical patients (49%) with no deaths seen in mild and severe cases. Lower case-fatality rates were identified in patients ages 70 to greater than 80 years. Case-fatality rate was elevated among those with preexisting comorbid conditions—10.5% for cardiovascular disease, 7.3% for diabetes, 6.3% for chronic respiratory disease, 6.0% for hypertension, and 5.6% for cancer [25].

## 3 Mechanism of SARS-CoV2

*Zhang et al.* (2020) demonstrated that all coronaviruses (CoV) have an analogous spike structure on their surfaces. In SARS-CoV-2, part of the spike (S) protein on the virus is used to bind to a receptor on the host cell and to fuse through the cell membrane. The receptor for SARS-CoV-2 is the angiotensin-converting enzyme 2 (ACE2) [26]. After binding to ACE2, the S protein is cleaved and prepared for the next steps - fusion and entering the cell - where endocytosis plays a major role in completing the subsequent steps [26]. Following that, the viral genome is exposed and translated inside the host's cell, all of the translated proteins that form the virus' particles aggregate inside the endoplasmic reticulum-Golgi

intermediate compartment, and then they are constituted in specific small vesicles in order to be transported to the extracellular compartment, thus infecting other cells [26]. In terms of receptor affinity, many studies have pointed out that the affinity of SARS-CoV-2 to human ACE2 is higher than that of Severe Acute Respiratory Syndrome coronavirus (SARS-CoV), which makes SARS-CoV-2 more contagious between people [26].

While angiotensin converting enzyme (ACE) yields angiotensin II (Ang II) from angiotensin 1 (Ang I), ACE2 yields Ang 1-7 from Ang II; Ang II causes vessels to constrict and induces proliferation (angiogenesis), while Ang 1-7 renders vessel dilation and limits cell growth/replication. When the balance between Ang II and Ang 1-7 is disturbed (Ang II outweighs Ang 1-7), acute lung injury will occur, and this is what happens when SARS-CoV-2 binds to ACE2, a receptor found on nearly all cells in human body, decreasing the production of ACE2 in the cell [26]. A genetic study demonstrated that ACE2 contains many genes that enhance viral strength during its lifecycle, and it concluded that ACE2 production increases SARS-CoV-2 viral load in the organs of the body [26].

## 4 Clinical Effects of COVID-19

### 4.1 Respiratory

*Hu et al.* (2020) conducted a metanalysis of 21 published trials to evaluate prevalence of COVID-19 symptoms, comorbidity, complications, and other outcomes in patients in China and Singapore [27]. The meta-analysis revealed hypertension and diabetes were the most common comorbidities associated with increasing severity of the SARS-CoV-2. However, the main obstacles in the treatment recovery were found to be ARDS and acute lung injury (ALI). As of June 25, 2020, the CDC also provided list of health conditions that are detrimental to severity of COVID-19 illness: moderate to severe asthma, pulmonary fibrosis, smoking and immunocompromised state due to corticosteroid use or immunosuppressant medications [27]. An Ex-vivo study conducted by *Chu et al.* (2020) compared infection and replication of SARS-CoV-2 and SARS-CoV in human lung tissues. The study revealed SARS-CoV-2 is 3.20-fold more infectious than SARS-CoV in human lung tissue [28].

Primary cause of death in COVID-19 is progressive respiratory failure secondary to diffuse alveolar damage [29]. Human lung cells normally express ACE2 receptors. *Ackermann et al.* (2020) examined 7 autopsied lungs from known positive COVID-19 patients and compared them with uninfected patients who died from ARDS related to influenza A (H1N1) and uninfected control lungs [29]. The study revealed immunohistochemical analysis of ACE2 in COVID-19 infected group, measured in Standard Deviation ( $\pm$ SD) as “cells per field of view” were  $0.25 \pm 0.14$  in comparison to  $0.35 \pm 0.15$  and  $0.053 \pm 0.03$  in influenza and uninfected control group respectively. Furthermore, ACE2 positive lymphocytes were not discovered in the alveoli of the control group but were present in both COVID-19 and Influenza groups, slightly higher in COVID-19 group [29]. Research has now shown ACE2 involvement in COVID19 is not limited to a role of a receptor on host cell where COVID-19 binds and enters the cell, but also involved in regulation of the infection, including immune response with cytokine secretion and replication of viral genome [30].

ARDS is caused by direct or indirect injury to the lung because of an acute systemic inflammatory response triggered by COVID-19 [30]. Studies reported dry cough (59.4-82%) as the most common respiratory manifestation of COVID-19, which suggests damage to epithelial lining as there is no sputum production [31]. Although COVID-19 affects multiple organ systems, the incidence of ARDS (15.6-31%) is higher in comparison to other organ injuries. This is secondary to damage to epithelial cell lining of the alveolar cells. Endothelial cells are the deeper layer of blood vessels in all organs, and therefore it is possible that these cells are not involved in earlier manifestation of COVID-19, therefore other organs are less involved [31]. Patients with low oxygen index are considered to have severe respiratory failure and will need

chest CT imaging (Xray and CT), which may show a mixed pattern of ground-glass appearance and consolidation [31]. However, despite severity seen on imaging, patients may not be experiencing dyspnea and have stable tissue perfusion, indicated by normal lactate level. Despite inconsistency between laboratory, imaging and symptoms experienced, these patients are to be monitored closely, as their condition may deteriorate rapidly [31]. Blood carbon dioxide is used as an indicator for invasive mechanical ventilation [31].

As per Berlin criteria, a patient is diagnosed with ARDS if the symptoms developed within 1 week of clinical injury [31]. *Huang et al.* (2020) reported median time of onset of symptoms for ARDS was 9.0 days amongst 41 COVID-19 cases vs. 8.0 days reported by *Wang et al.* (2020) in 138 cases [33, 34]. However, *Zhou et al.* (2020) reported median of 12.0 days for ARDS illness onset [35]. These studies show that Berlin criteria for ARDS do not apply to ARDS seen in COVID-19 patients. Patients diagnosed with ARDS are generally treated with high flow nasal oxygen [31, 36]. Corticosteroids may also help reduce inflammation and fibrosis and may lower mortality in severe ARDS patients. However, more research is needed to assess impact of COVID-19 on long term prognosis of these patients [36].

## 4.2 Cardiovascular

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes COVID-19, is a novel virus of interest for the cardiovascular system as it causes deleterious effects to a host of higher-risk populations. Persons in higher-risk populations include those who have coronary artery disease, diabetes mellitus, hyperlipidemia, hypertension, and obesity [37, 38, 39]. Age is another risk factor of consideration as an elderly individual ( $x > 60$ -years-old) infected with SARS-CoV-2 developed more systemic complications [39]. Any individual with the above risk factors and infected with this virus will have a poor prognosis due to increased expression of angiotensin-converting enzyme 2 and an increased propensity for cytokine storm [37, 39].

The mechanism of action of cardiovascular damage once SARS-CoV-2 binds to angiotensin receptor enzyme 2 (ACE2) is as follows: ACE2 is normally expressed in the heart, kidneys, lungs (particularly type-2 alveolar cells), and other organs [37, 38, 39]. Patients with the above risk factors and on appropriate anti-hypertensive therapies (lisinopril, losartan) affecting the renin-angiotensin-aldosterone system (RAAS) will have increased expression of ACE2. Once SARS-CoV-2 binds to ACE2, this action alters ACE2 signaling pathways leading to vasodilatation and suppressed cell growth. Acute lung injury, in the form of severe pneumonia, puts stress on the heart leading to acute hypoxia and decompensation [38, 39]. As a result, coronary arterial flow increases to keep up with increased myocardial oxygen demand. Lack of oxygen from decreased blood flow leads to direct myocardial damage (apoptosis), whereas increased shear stress upon coronary arteries can result in plaque rupture and eventually myocardial infarction [37, 38]. At the same time this occurs, the immune system responds with systemic inflammation through the release of pro-inflammatory cytokines (Interleukins 1 and 6, tumor necrosis factor-alpha) resulting in systemic inflammation, multiorgan failure, and depressed myocardial function [39]. Other important causes of decreased myocardial function include the development of acute coronary syndrome, acute myocarditis, disseminated intravascular coagulation (pro-coagulation state), electrolyte imbalances (hypokalemia), shock (cardiogenic), and stressed-induced cardiomyopathy [39].

A workup for COVID-19 will reveal that patients will either be asymptomatic or present with a variety of symptoms [40]. Common symptoms of COVID-19 include anorexia, a dry cough, dyspnea, fever, fatigue, and myalgia [40]. Concerning the cardiovascular system, a patient may present with chest pain, dyspnea, and heart palpitations. A workup for acute coronary syndrome begins once a patient presents for further evaluation [38, 39]. Workup will reveal an elevated cardiac troponin I (cTnI) and an abnormal EKG

demonstrating either ST elevation or depression, along with brady/tachyarrhythmias [39]. In the setting of acute hypoxia, lab work may show an elevated D-dimer, fibrin degradation products, and fibrinogen [37]. Severely elevated values of cTnI or D-dimer indicate a poor prognosis. Once a patient has severe COVID-19 as a confirmed diagnosis and is transferred to the intensive care unit (ICU) setting, the disease course usually worsens. ICU patient may exhibit acute heart failure, elevated blood pressure, and persistent cTnI elevation. If and when a patient becomes discharged from the hospital setting, patients may experience abnormalities with glucose and lipid metabolism [37].

Management will depend on disease severity. Hospital admissions will require the following considerations [37, 38, 39]:

- Anticoagulation: Heparin or low-molecular-weight heparin for seven days. Drug-drug interactions should be monitored with concomitant use of anti-viral drugs. Low-molecular-weight heparin is preferred in the ICU setting.
- Anti-hypertensives: RAAS inhibitors (lisinopril, losartan) should be continued in the hospital setting if previously prescribed. There is some controversy regarding higher ACE2 expression.
- Immune modulating drugs: Prednisone and IL-6 inhibitors (Tocilizumab) should be considered only when the case is severe and cytokine storm is imminently anticipated.
- Mechanical cardiopulmonary support: Further research is required given variable survival rates with modalities, not limited to extracorporeal membrane oxygenation (ECMO), intra-aortic balloon pump, and veno-arterial ECMO.
- Testing: Testing should only be warranted if it contributes to meaningful management of complications of COVID-19

Follow-up in the outpatient setting will need constant monitoring of blood pressure, glucose, and lipid regulation [37].

### 4.3 Cytokine Storm

Cytokine storm is an informal term that refers to the dysregulated release of proinflammatory cytokines as a reaction to infection and various stimuli [41]. In a wider sense, cytokine storm may pertain to hyperactivity in the immune response as it entails releasing various mediators such as interleukins, interferons, chemokines, tumor-necrosis factors, and other mediators [42]. During the ongoing coronavirus disease 2019 (COVID-19) pandemic, there has been an increasing number of severe COVID-19 cases deteriorating as a result of a cytokine storm. Critically ill or severely ill patients deteriorate suddenly in the later stages of COVID-19 or the recovery phase. An important challenge is to distinguish a *dysregulated* inflammatory response from an *appropriate* inflammatory response in the pathophysiology of COVID-19. This is due to the implications surrounding how “cytokine storm” is defined. When discussing the cytokine storm in the context of an inflammatory response, it is implied that increasing cytokine release is damaging to host cells [42]. Patients who are at risk for developing cytokine storm include those with comorbid illnesses including coronary artery disease, obesity, cancer, primary immunoglobulin deficiencies, autoimmune conditions, and recipients of immunosuppressive therapies [43]. Patients with these underlying comorbid conditions are at higher risk of developing severe COVID-19 and concurrent with this, an increased risk of developing a cytokine storm. As such, special consideration must be given to these high-risk populations when it comes to guidelines in their management when infected with COVID-19.

SARS-CoV-2) is a novel virus of interest for the immune system as it causes immune dysregulation. Once infected with SARS-CoV-2, it manifests a myriad of symptoms in a patient. A patient can be asymptomatic or exhibit anorexia, a dry cough, dyspnea, fever, fatigue, and myalgia. Such symptoms are associated with a high rate of human-to-human transmission. Several cytokines implicated in the production

of these symptoms include interleukins 2 (IL-2) and 6 (IL-6) as well as tumor necrosis factor-alpha (TNF- $\alpha$ ). A consequence of persistent IL-2 levels is capillary leak syndrome which is characterized by increasing capillary permeability to proteins leading to edema, hypotension, acute respiratory failure, and kidney injury [44].

Relevant evidence from severe cases of COVID-19 suggests that proinflammatory responses play a role in the pathogenesis of this disease [44]. Several proinflammatory cytokines (IL-6, IL-8, IL-1 $\beta$ , granulocyte-macrophage colony-stimulating factor, and reactive oxygen species), and chemokines (CCL2, CCL-5, IFN $\gamma$ -induced protein 10, and CCL3) contribute to the occurrence of Acute Respiratory Distress Syndrome (ARDS). These proinflammatory responses contribute to cytokine and chemokine response dysregulation in the setting of high virus titers following SARS-CoV-2 infection, leading to an inflammatory cytokine storm. This inflammatory cytokine storm is most often accompanied by immunopathological changes in the lungs [44]. Immunopathological lung changes may be a result of rapidly increasing cytokines and chemokines attracting numerous inflammatory cells such as neutrophils and monocytes. These neutrophils and monocytes, in turn, cause an excess in inflammatory cell infiltration into lung tissue, resulting in lung injury [44]. It can be postulated from these immunopathological lung changes that dysregulated cytokine and chemokine responses by SARS-CoV-2 infected cells play an essential role in the pathogenesis of COVID-19.

A distinguishing factor in cytokine storm is persistent fever and constitutional symptoms such as joint pain, muscle pain, weight loss, headache, and fatigue. When a cytokine storm occurs, systemic inflammation spreads across different organ systems leading to manifestations such as loss of vascular tone presenting as hypotension, vasodilatory shock, and progressive organ failure [44]. ARDS results and contributes further to multiple-organ failure in quick succession, resulting in sudden death. Cytokine storm suppression is of utmost importance to prevent detrimental deterioration of COVID-19 patients thus increasing their chances of recovery [41]. Sun, X. *et al.* (2020) reported a retrospective study of 41 COVID-19 patients which showed patients presented with a myriad of symptoms ranging from an asymptomatic state to ARDS [45]. Severe complications associated with COVID-19 include ARDS, a “Kawasaki-like syndrome” in children, inflammatory myocarditis, myocardial infarction, cardiac arrest, multiple organ failure, ischemic stroke, secondary hemophagocytic lymphohistiocytosis, acute pulmonary embolism, bacterial pneumonia [45].

At present, there is still a lack of consensus in the diagnosis and management of a cytokine storm. This poses a challenge in tackling COVID-19 due to a lack of established protocols and treatment. High virus titers and immune dysregulation have been largely associated with increased morbidity and mortality of COVID-19 patients. It is therefore highly encouraged that prompt interventions in the early stages of COVID-19 are done to control proinflammatory responses. Theoretical treatment strategies proposed at present include immunomodulators such as IFN- $\lambda$ , corticosteroid therapies, intravenous immunoglobulin, IL-1 family antagonists, IL-6 antagonists such as Tocilizumab, IFN- $\alpha\beta$  inhibitors, TNF blockers, chloroquine, ulinastatin, oxidized phospholipids, sphingosine-1-phosphate receptor 1 agonist therapy, stem cell therapy, blood purification treatments, and TLR-7 agonists. Targeting the endothelial Slit-Robo4 pathway is recommended using the aforementioned proposed treatment strategies, as activation of this pathway is found to improve vascular permeability in COVID-19 patients thus decreasing cytokine storm occurrence [45].

#### 4.4 Renal

Most patients with COVID-19 have mild symptoms, but about 5% develop severe symptoms, which can include acute respiratory distress syndrome, septic shock, and multiple organ failure. Patients

with kidney disease exhibited worse clinical outcomes when infected with SARS-CoV-2 [46]. In addition to COVID-19 causing AKI in 5-15% of the cases, it also impacts patients with chronic kidney disease (CKD), patients on chronic replacement therapies, and patients with a kidney transplant. Patients with end-stage renal disease (ESRD) are particularly vulnerable to severe COVID-19 due to the older age and high frequency of comorbidity, such as diabetes and hypertension, in this population [47].

The ACE2 receptor is normally expressed in the heart, kidneys, lungs (particularly type-2 alveolar cells), and other organs [37]. The SARS-CoV 2 binds to this receptor causing direct cellular injury resulting from viral entry through the receptor (ACE2), which is highly expressed in the kidney. The virus's deleterious effects on the kidney are thought to be multi factorial including a wide range of potential mechanisms. Targeting of ACE2 by SARS-CoV-2 combined with its selective tropism for kidneys, results in angiotensin dysregulation, innate and adaptive immune pathway activation, and hypercoagulation to result in tubular injury and AKI associated with COVID-19.

Organ crosstalk between the injured lungs, the heart, and the kidney may further propagate injury [48]. There seems to be a close relationship between alveolar and tubular damage due to cytokine overproduction, which establishes the "lung-kidney axis" in ARDS. ARDS also may cause renal medullary hypoxia, which is an additional insult to tubular cells [49]. Cardiomyopathy and acute viral myocarditis seen in severe COVID-19 cases can both contribute to renal venous congestion, hypotension and renal hypoperfusion, leading to a reduction in glomerular filtration rate [50]. The resulting fluid imbalances contribute to pre-renal AKI. The pro-inflammatory cytokines elicited by the viral infection or the resultant rhabdomyolysis cause toxic tubular damage predominantly affecting the proximal convoluted tubules (PCT). Non-specific mechanisms include drug nephrotoxicity, high levels of PEEP in patients requiring mechanical ventilation, and nosocomial sepsis. The interactions may facilitate Acute kidney injury (AKI) commonly seen in critically ill patients, affecting ~20–40% of patients admitted to intensive care, and is considered as a marker of disease severity and a negative prognostic factor for survival [51]. Several studies have highlighted changes in urinary sediment, including proteinuria and hematuria, and evidence of urinary SARS-CoV-2 excretion, suggesting the presence of a renal reservoir for the virus [52].

Notably, the overall burden of AKI in COVID-19 might be underestimated, as creatinine values at admission might not reflect true baseline kidney function, and previous serum creatinine values might not be readily available [53]. Patients with CKD, and especially those with end-stage renal disease and with renal replacement therapy, are known to have impaired immune function, and this could contribute to greater SARS-CoV-2 infection susceptibility [54]. A majority of patients with ESRD are treated with some form of dialysis. This population must take strict precautions and follow the recommended CDC guidelines to prevent exposure and must be preemptively monitored for the development of symptoms (eg: cough and fever) suggestive of COVID-19 infections. Most patients with CKD and associated comorbidities are on ACE inhibitors and ARBs. There was speculation that patients with COVID-19 who are receiving these agents may be at increased risk for adverse outcomes due to up-regulated expression of the ACE2 receptor. However, there is no evidence to support an association between renin angiotensin system inhibitor use and more severe disease. Some studies even suggest a possible protective effect of these agents in COVID-19 Induced Acute Kidney Injury [55]. Therefore, treatment with these agents should be continued (unless there is an indication for discontinuation such as hyperkalemia or hypotension)

No vaccine has been developed against the SARS-CoV-2 virus to date. The critical aspect of management is supportive care. Implementation of the Kidney Disease: Improving Global Outcomes (KDIGO) supportive care guideline (e.g., avoidance of nephrotoxins, regular monitoring of serum creatinine and urine output, consideration of hemodynamic monitoring) in critically ill patients with kidney involvement is likely to reduce the occurrence and severity of AKI in COVID-19. The evaluation of AKI



in COVID-19 patients should follow the general approach to workup and diagnosis of AKI, utilizing the broad framework of prerenal, intrarenal, and postrenal causes.

In patients with suspected or confirmed COVID-19 who develop AKI, an emphasis should be placed on optimization of volume status to exclude and treat prerenal (functional) AKI, while avoiding hypervolemia, which may worsen the patient's respiratory status. If conservative management fails (volume management, discontinuation of nephrotoxic medications, etc.), renal replacement therapy (RRT) should be considered in patients with volume overload, especially those with refractory hypoxemia. In patients with COVID-19 and AKI, early initiation of RRT and sequential extracorporeal organ support (ECOS) seem to provide adequate organ support and prevent progression of disease severity [56]. In the patients who developed AKI from COVID-19 infection, around 1.5-9% of them required RRT in the form of continuous renal replacement therapy (CRRT) [57].

There is increased risk of clotting of hemodialysis filters due to cytokine-induced hypercoagulability, so clinicians should attempt to anticoagulate all patients that are on dialysis if there is no contraindication [58]. In the absence of specific anti-SARS-CoV-2 treatments, supportive care and use of sequential extracorporeal therapies for critically ill patients with evidence of kidney involvement provide a life support bridge to recovery and enhance the probability of a favorable outcome [50].

#### 4.5 Diabetes

One of the organs affected in COVID19 is the pancreas. As it has come to be a known observation that patients who are suffering from Diabetes Mellitus (DM) tend to have more severe outcomes due to COVID-19 disease in addition to being more susceptible to acquiring COVID-19 infection [59]. Due to these reasons, *Lian et al.* conducted a study in which they divided the study population into two groups: younger than 60 years and older than 60 years. The authors showed that a variety of comorbidities, including DM, were more commonly found in the older than 60 years group [60]. Therefore, the age difference is most likely one of the most important reasons for risk that is attributed to diabetic patients with COVID-19 [59].

A study by *Hoffman et al.* (2020) suggested that ACE2, converts angiotensin II to angiotensin I-7 which also causes vasodilation, is the receptor used by the Coronavirus (SARS-CoV-2) to bind to their target cells which “is expressed by the epithelial cells of the lungs, intestine, kidney and blood vessels” [61]. As mentioned in *Fang et al.* (2020), patients with types I and II DM who are treated with Angiotensin-Converting Enzyme (ACE) inhibitors and Angiotensin II type-I receptor blockers (ARBs) demonstrated increased expression of Angiotensin-Converting Enzyme 2 (ACE2) [62]. There has been a noted increase in ACE2 expression by Thiozolidinadiones. Given that DM is a hyper-inflammatory condition, *Tadic et al.* (2020), mentions a few possible mechanisms for DM being an independent risk factor for COVID-19 infection. First being inflammation, secondly, hypercoagulable state, and last but not the least, dysfunctional sympathetic nervous system (SNS) and activated Renin-Angiotension-Aldosterone system (RAAS) [59]. It is known that RAAS function is already significantly modified in diabetics [61]. Therefore, in summation, a diabetic person would have more expression of ACE2 as such, on the treatment of ACEI and/or ARBs, in conjunction with certain anti-diabetic medications that can demonstrate increased susceptibility to SARS-CoV-2 which acts through ACE2. Therefore, when a diabetic, with altered RAAS, is infected with COVID-19, he or she may undergo “acute change in the activity of ACE2” which can cause a trigger for the hypercoagulable and hyper-inflammatory state [62]. *Guo et al.* (2020)'s case-control study suggested that patients with DM in absence of other comorbidities infected by SARS-CoV-2 still demonstrated a “higher risk of severe pneumonia, uncontrolled inflammatory response, higher levels of tissue injury-related enzymes, and higher hypercoagulable state” [63, 64]. They also found that the serum inflammatory biomarkers levels were

significantly raised in diabetics in comparison to those without DM; these biomarkers include C-reactive protein, D-dimer, IL-6, serum ferritin, and coagulation index [64].

Another study by *Wang et al.* (2020) found that 17% of patients in their study experienced pancreatic injury defined by an abnormal lipase and amylase levels [65]. However, clinical symptoms of severe pancreatitis were not experienced by these patients. Besides, ACE2 being expressed by the epithelial cells of the lungs, intestine, kidney and blood vessels, is also expressed highly in pancreatic islet cells. This in theory would mean that SARS-CoV-2 infection can cause massive islet cell damage which can lead to acute diabetes [64, 65]. It is, however, still unclear about the exact “pathogenesis of increased mortality and morbidity of COVID-19 in patients with diabetes”. There is also still less understanding about the direct pancreatic injury and it is highly recommended to continue further research.

*Muniyappa et al.* (2020). also discusses potential mechanisms that may play a role in increasing the susceptibility for COVID-19 in patients with DM. *Munniyapa et al.* mentions 5 main mechanisms; “1) higher affinity cellular binding and efficient virus entry, 2) decreased viral clearance, 3) diminished T cell function, 4) increased susceptibility to hyperinflammation and cytokine storm syndrome, and 5) the presence of CVD” [66]. In addition to ACE2, SARS-CoV-2 also acts through another receptor DPP4. Now it has come to understanding in two meta-analyses studies that DPP4 inhibitors, which are widely used in diabetics, increase the risk for a variety of infections, whereas, “a third meta-analysis showed that there is no increased risk of infections with DPP4 inhibitors”. For these reasons, it is highly important to study whether the DPP4 inhibitors would increase the susceptibility or severity of SARS-CoV-2 infection by conducting clinical trials [67].

In the current COVID-19 pandemic, due to lockdowns, diabetic management is now difficult due to travel restrictions, however, *Singh AK et al.* (2020) mentions modern innovations like telemedicine that can be specifically crucial for diabetes management [68]. It is important to note that glycemic control is very important in diabetic patients with COVID-19. SGLT-2 inhibitors should be discontinued due to the risk of dehydration and euglycemic ketosis [68]. *Singh AK et al.* (2020) further suggest that metformin may also need to be stopped if a diabetic patient experiences vomiting or poor oral intake [68]. Other anti-diabetic medications that include sulfonylureas and insulin may have to be altered depending upon blood glucose levels [68]. Diabetic patients should maintain a regular diet consisting of balanced amounts of protein, fiber, and limited saturated fats, which are crucial to maintaining good glycemic control. Regular indoor exercise is also beneficial to good glycemic control [68]. Medication use should also be adhered as well [68]. Telemedicine is highly valuable for diabetic patients and they should be explained that telemedicine services are available to them to consult their physician regularly. Diabetic patients must be educated on foot care as well to avoid diabetic-related complications [68]. In summary, diabetic patients must receive proper education on proper glycemic control and strict medication use to maintain their DM [68].

#### 4.6 Gastrointestinal

As per studies by *Gu et al.* (2020), *Cheong et al.* (2020), *Patel et al.* (2020), nearly 50% of COVID-19 patients have presented with concurrent gastrointestinal (GI) manifestations like diarrhea (most common), nausea, vomiting, and abdominal pain; in some cases, anorexia, dysgeusia, anosmia, and hematochezia have also been reported [64, 69, 70]. The demographics that are most vulnerable to pulmonary and extrapulmonary (like gastrointestinal) manifestations include older adults, smokers, HIV patients, immunocompromised, and those who suffer from comorbidities [71]. Moreover, patients with underlying inflammatory bowel disease (IBD) are also at increased risk of contracting COVID-19 [64, 72]. The GI manifestations in COVID-19 are noted to be present in both adult and pediatric populations ranging from 10 months to 78 years old, with an average age of 46.1 years [64]. It is also important to note, there was a

higher incidence of vomiting seen in children as compared to adults even though diarrhea was the most common symptom in both these populations [64].

Based on recent studies of GI manifestations in COVID-19 patients, it has been commonly hypothesized that the infection can be transmitted through the fecal-oral route. Besides confirming the presence of SARS-CoV-2 RNA in feces, also confirmed the long periods of viral shedding lasting approximately two weeks to over a month, supporting the hypothesis of viral replication occurring in the gastrointestinal tract [64]. Additionally, the presence of the SARS-CoV-2 RNA in stool was noted to be independent of its presence in the respiratory samples since it was found that the virus can continue to be present in the fecal matter even after the respiratory symptoms have subsided and the respiratory specimens (including nasopharyngeal swabs) have tested negative for SARS-CoV-2 [64]. SARS-CoV-2 is likely to be transmitted by both symptomatic as well as asymptomatic patients causing GI infectivity with the incubation period estimated between 2 to 14 days [71].

*Cha et al.* (2020) concluded an association between pathogen, host, and environmental factors that can enhance the SARS-CoV-2 infectivity through the fecal-oral transmissibility. Although environmental influences such as close contact with infected persons (including symptomatic and asymptomatic patients), poor personal hygiene, and poor public sanitation play a significant role in infectivity, GI symptoms and their corresponding severity depend on the pathogen load in stool and saliva, viral shedding, the viability in the environment, infectious dose [71], and the extent of viral gene expression in enterocytes and stratified epithelial cells of the esophagus, which can cause the direct intestinal injury and infectivity [73].

SARS-CoV-2 can lead to GI manifestations through its interaction with specific cell receptors called angiotensin-converting enzyme 2 (ACE2), and host cellular transmembrane serine protease (TMPRSS) which, besides in the lungs pneumocytes, are also expressed in stratified epithelial cells of the esophagus, as well as absorptive enterocytes in the ileum and colon of the intestine [69, 72, 73]. This inflammatory response caused by SARS-CoV-2 infection leads to direct injury to the enteric system including its absorptive and epithelial enterocytes; consequently, resulting in malabsorption, and secretory diarrhea [64].

The study conducted by *Baryab et al.* (2020) and *Patel et al.* (2020) has suggested for fecal and saliva specimen testing in COVID-19 patients who have reported GI symptoms by confirming identification of the viral nucleic acid (SARS-CoV-2 RNA) in the stool and salivary samples through real-time reverse transcriptase-polymerase chain reaction (rRT-PCR technique) [64, 72]. In addition, they briefly mentioned that endoscopy and biopsy had further confirmed the presence of SARS-CoV-2 nucleocapsid protein in the enteric epithelium including, the esophagus, stomach, duodenum, and rectum. However, such diagnostic tools including, peg tube procedures, endoscopy, and colonoscopy can potentially pose a threat to viral transmission, thus limiting their usage [64, 71].

It is crucial to rule out other infectious etiologies including *Clostridium difficile* before treating COVID-19 patients for their enteric symptoms. Nausea and vomiting are managed conservatively with antiemetic medications, and in cases of bacterial coinfection, antibiotics are administered. Management is mainly focused on effective infection control through the use of Personal Protective Equipment (PPE), keeping the close contacts informed about the viral shedding (even during incubation and asymptomatic phase), encouragement of proper hygiene and hand-washing practices, and most importantly the adherence to social distancing guidelines [64].

Globally, a total of 326 patients with underlying inflammatory bowel disease (IBD) have reported being infected with COVID-19, 189 of which had Crohn's disease, while 135 cases had ulcerative colitis [71]. A study by *Baryab et al.* (2020) documented the upregulation of receptors like ACE2 and TMPRSS, and increased cytokine storm in patients with IBD, making them vulnerable to contracting COVID-19, and an increased likelihood to report increased severity in symptom manifestation [72]. Thus, precautionary

measures recommended to patients with IBD include proper hand hygiene, PPE, face masks, avoidance of hospital settings, and most importantly to adhere to social distancing guidelines in public settings. *Cha et al.* (2020) and *Baryah et al.* (2020) in their recent studies summarized that IBD patients who were managed by immunomodulatory agents that attenuate the inflammatory response may protect them from contracting COVID-19 as well as developing severe conditions; however, since they act as immunosuppressants, their recommendations may vary during an active SARS-CoV-2 infection depending on the medications, presence, and severity of SARS-CoV-2, as well as IBD flare-ups [71, 72]. In these cases, patients may need to continue with their ongoing regimens of 5-aminosalicylic acid (5-ASA) or may be asked to withhold some treatments (including prednisone if dose is  $\geq 20$  g/d, tumor necrosis factor, and other immunomodulators and immunosuppressants) if positive for COVID-19, and reinstated after the viral clearance [71, 72].

Most of the studies discussed were conducted in China, thus the applications of these findings and recommendations on a global level are limited. There is also a variance between the findings of the studies discussed. Although the studies have confirmed the presence of SARS-CoV-2 in the fecal matter and subsequent viral shedding, there is no proven evidence to confirm the fecal-oral transmission and replication of the virus. More studies need to be conducted; however, current findings have provided promising insights into the critical effects of COVID-19 on the GI system.

#### 4.7 Liver Disease

Liver injury associated with COVID-19 is defined as any clinical or laboratory abnormality related to liver function that appears in patients either with or without a pre-existing liver disease [74]. Liver function derangements with Covid-19 infection are usually transient and mild. The most frequent derangements observed is an elevated Alanine aminotransferase (ALT) and Aspartate transferase (AST) level, with the incidence ranging from 2.5%-50.0% and 2.5%-61.1% respectively. Total bilirubin levels are elevated from 0%-35.3% of Covid-19 positive patients. Elevated alkaline phosphatase (AKP) and gamma-glutamyl transferase (GGT) levels have been reported in patients with comorbid NAFLD and this was associated with a more severe disease course and a poor prognosis [75-84].

Studies have found moderate microvascular steatosis, mild lobular and portal activity, mild sinusoidal dilatation and an increase in mitotic cells and ballooned hepatocytes on liver biopsy of Covid-19 patients [81, 82, 83]. A few mechanisms have been proposed to explain the liver injury patterns.

1. Cytotoxicity: The SARS-CoV-2 may directly infect hepatocytes and cholangiocytes - since the receptor of the virus, angiotensin-converting enzyme 2 (ACE2) is present on both types of cells and induce apoptosis via a caspase-dependent pathway [74]. It is important to note, however, that biopsy of liver tissue from a patient who died from COVID-19 has shown no viral inclusions [74-81].
2. Cytokine storm: Several studies have reported that COVID-19 patients with abnormal liver function have higher serum pro-inflammatory cytokine and chemokine levels including C reactive protein (CRP), procalcitonin, serum ferritin, LDH, D-dimer, IL-6, IL-2 and lymphopenia – a consequence of immune activation [74-81]. This suggests that the liver injury seen in SARS-CoV-2 might be a consequence of the cytokine storm.
3. Hepatotoxic drugs: the use of hepatotoxic drugs including lopinavir, ritonavir, remdesivir, chloroquine, tocilizumab, uminefovir, Chinese traditional medicine, antibiotics, antipyretics and analgesics is common in Covid-19 patients [75-84].
4. Hepatic congestion: high levels of positive end expiratory pressure during mechanical ventilation can lead to elevated right atrial pressures and hepatic congestion.

The incidence of liver injury is higher in patients with severe COVID-19 infection when compared with patient with non-severe disease [75-84]. In a recent meta-analysis it was observed that higher serum levels of Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), total bilirubin and lower serum levels of albumin, were associated with a significant increase in the severity of COVID-19 infection. LDH was observed to be higher in patients with abnormal liver function in another study [75-84]. Although low albumin is a marker of severe infection and poor prognosis, it is usually not accompanied by other markers suggestive of liver failure, such as hyperammonemia, hyperbilirubinemia, hypoglycemia or prolonged coagulation times [75-84]. *Fan et al.* (2020) observed that patients with abnormal liver function had longer length of stay when compared with patients with normal liver function. However, not all studies have found a significant association between deranged liver function tests and poor outcomes [76]. For instance, *Wu et al.* (2020) found no significant differences in the liver functions tests of non-severe versus severe patients [81].

#### 4.8 Rheumatoid Arthritis (RA)

A study recently published in *Autoimmunity Reviews* has suggested that the combined effects of impaired immunity and the use of corticosteroids and immunosuppressive drugs increases the risk of bacterial and viral infections in RA patients [85, 86]. According to the Global Rheumatology Alliance Global Registry, patients preferably age >65 y.o. with acute flares of active rheumatic disease, living in a health care facility and other associated comorbidities are at increased risk of severe illness. The Italian Society for Rheumatology performed a retrospective study to monitor impact of COVID-19 in patients with autoimmune rheumatic diseases. *Carlo Alberto Scirè et al.* (2020) recruited 232 (36% males) elderly patients (mean age 62.2 years), who used corticosteroids (51.7 %) suffering from multiple comorbidities. Rheumatoid Arthritis was the most common disease (34.1%), followed by spondyloarthritis (26.3%), connective tissue disease (21.1%) and vasculitis (11.2%). 69.4% patients had an active disease [86]. Typical COVID-19 clinical presentation occurs, with systemic symptoms (fever and lack of energy) and respiratory symptoms. The overall outcome was severe with 69.8 % required hospitalization, 55.7 % required respiratory oxygen support, 20.9 % needed invasive ventilation or 7.55% needed mechanical ventilation and 19 % patients died. Male sex was a poor prognostic factor. Immunomodulatory treatments were not significantly associated with an increased risk of ICU admissions and death [86].

Along with other common respiratory symptoms of COVID-19, musculoskeletal symptoms can develop. In a recent study, arthralgia was reported in 15% and myalgia in almost 44% in COVID-19 patients, although COVID-19 is not well-known to cause clinical arthritis [77, 87, 88, 89]. However, high dose glucocorticoids diminish the musculoskeletal symptoms of COVID-19. We hypothesized that the COVID-19 pandemic could erroneously cause an increase in RA cases. There is still no report which indicates that people develop autoimmune inflammatory arthritis, such as RA, after being infected by SARS-CoV-2 or any of the other six known human coronaviruses.

The release of pro-inflammatory cytokines in the alveolar membranes during severe COVID-19 infection share connections with the primary cytokines (IL-1, IL-6, IL-17, TNF) targeted in the treatment of RA. Both diseases induce extensive tissue destruction and organ failure. COVID-19 is characterized by a robust host immune response, elicited by alveolar epithelial cell damage and T cell activation in the lungs that causes uncontrolled local production of pro-inflammatory effector cytokines leading to the attraction of a vast majority of neutrophils and macrophages to the lungs. Barrier damage, T-cell activation, effector cytokine production, and neutrophil influx (the critical features of synovitis) are commonalities between COVID-19 and RA. Whether cytokine inhibition can block this process remains to be established, but a rationale exists for this approach. The use of cytokine inhibitors in COVID-19 is balanced by the fact that

a pathological hyper-inflammatory state is driving the pathology and might require therapeutic cytokine inhibition [90].

In a retrospective study, the prevalence of autoimmune rheumatic diseases among 902 ICU patients with SARS-CoV-2 pneumonia was evaluated [85]. Four hundred and fifty records (49.9%) obtained from the Moscow hospitals, 123 records (13.6%) from the Moscow province and 329 records (36.5%) from the hospitals located in fifty-two geographical regions of the Russian Federation. Autoimmune diseases like rheumatoid arthritis, systemic sclerosis, psoriatic arthritis, systemic lupus erythematosus and ankylosing spondylitis were identified in 10 (1.1%) of 902 ICU patients with COVID-19. The local physicians reported the diagnosis. As per expectations, rheumatoid arthritis was the most common rheumatic disorder, given its higher prevalence in the general population. Six patients were >60 years of age. Seven patients had concurrent cardiovascular diseases (arterial hypertension, atrial fibrillation, previous myocardial infarction, or stroke), and three patients had type 2 or steroid related diabetes. Five patients (50%) died.

We initially assumed that immunocompromised patients with autoimmune rheumatic diseases were likely to present with a more severe course of COVID-19 requiring oxygen support and admission to ICU. However, the total prevalence of inflammatory rheumatic disorders among ICU patients with SARS-CoV-2 pneumonia was low (1.1%) as compared to the general population (1%–2%). Moreover, most critically ill patients with rheumatic disease had multiple comorbidities like cardiovascular diseases, obesity and diabetes mellitus that can contribute to the development of ARDS. That's why any definite conclusions regarding the risk of severe COVID-19 in rheumatic patients cannot be made, since we do not know the total number of infected patients with autoimmune rheumatic diseases in Russia. As a rule, patients with any chronic illness are at increased risk of contracting respiratory infections frequent outpatient clinic visits or hospitals where they can have exposure with infected individuals [85].

No specific treatment for COVID-19 warrants symptomatic care, so the control of disease activity is the mainstay of management of RA patients during COVID-19. Also, the management of comorbidities and extra-articular features plays a crucial role in the control of the disease. Recommendations regarding the use of immunomodulatory drugs during COVID-19 are as follows [91, 92, 93].

- NSAIDs: May be used in active arthritis but stopped in case of severe respiratory symptoms with diagnosed or suspected COVID-19.
- Steroids: Corticosteroids are the mainstay of initial treatment in acute RA flares. Lowest-possible dexamethasone use is recommended in patients with moderate to severe COVID-19. Sudden discontinuation should be avoided.
- csDMARDs: May be used, but Sulfasalazine, Methotrexate and Leflunomide should be stopped in patients with diagnosed or suspected COVID-19.
- bDMARDs, tsDMARDs: May be considered in moderate to severe RA, JAK inhibitors and non-IL-6 biologics should be discontinued in patients with diagnosed or suspected COVID-19. Switching from intravenous to subcutaneous form can be considered if available. Increase of dosing-interval or reduction of RTX can be considered.
- Pneumococcal, influenza vaccine and Vitamin D: These are also recommended for suspected patients.

For uncomplicated infections treated in the outpatient setting, DMARDs and other biological agents may be resumed within 7-14 days of symptom resolution. For asymptomatic patients who tested positive for COVID-19, treatment may be resumed after 10-17 days of the positive report. The decision to resume treatment should be left to the treating rheumatologist, which should be done on a case by case basis.

## 4.9 Nervous System

Although the predominant clinical presentation is with respiratory disease, neurological manifestations are being increasingly recognized [94]. Olds & Kabbani (2020) raised the question of nicotine associated neurological comorbidity in COVID19 patients that the viral target receptor ACE2 is expressed in the brain and functionally interacts with nAChRs [95]. They considered neural cells and astrocytes (especially in the hypothalamus and brainstem) more prone to infection in smokers because nicotine stimulation of the nAChR was found to increase ACE2 expression within them. ACE2 signaling pathway is believed to counteract oxidative stress and neuroinflammation, thus, disruption in ACE balance can lead to neurodegeneration of dopaminergic neurons or impairment in cholinergic pathways which might participate in the progression of Alzheimer's disease [95].

For a given virus, the ability to infect certain cells, tissues, or even species while not affecting others is referred to as *viral tropism*. This viral tropism, allowing a virus to replicate in and affect certain body tissues, would then lead to the symptomatic presentation of that virus. A major factor that dictates this tissue selectivity is the virus' ability to bind and take over specific host cell surface receptors. Recent research on SARS-CoV-2 has shown that similarly to SARS-CoV, this virus can invade tissues by binding to the angiotensin-converting enzyme 2 (ACE2) receptor on certain host cells. It has been reported that the brain also expresses ACE2 receptors on glial cells and neurons and is most prominent in the brainstem, the paraventricular nucleus (PVN), nucleus tractus solitarius (NTS), and the rostral ventrolateral medulla which all play a role in cardiovascular regulation. [61, 96]

The neurological manifestations can be generally divided into two categories: central and peripheral. Central manifestations include headache, dizziness, impaired consciousness, encephalopathy, delirium, global confusion, syncope, seizures, gait difficulties, cerebrovascular events, encephalitis, and post-infectious autoimmunity. Peripheral disorders include isolated cranial nerve dysfunctions (i.e., impaired sense of smell and taste sensation), Guillain-Barré-syndrome, and myositis-like muscle injury. Although the majority of neurological symptoms develop throughout the course of illness, others such as acute strokes can be the initial presentation. [97]

As per *Berger et al* (2020), headache is a common symptom of COVID-19 being observed in up to 40% of patients [98]. Similarly, the contribution of CNS viral invasion by SARS-CoV-2 contributes to the frequently observed altered levels of consciousness in the severely ill COVID-19 patient as opposed to general systemic disease. Unsurprisingly, encephalopathy has been described. Patients with encephalopathy consequent to overwhelming infection and associated co-morbidities are likely to be the most common neurological complication. Several pathophysiological processes may be responsible for an increased risk of stroke with COVID-19. Severe disease is seen more often in older patients who often have comorbidities that increase their risk of stroke [98]. As per *Zhou et al.* (2020), markers of coagulation may be increased during infection, and disseminated intravascular coagulation has been observed [99]. Brain endothelial cells express ACE-2 receptors, and the potential exists for viral-induced vasculitis. Risk may be increased for both arterial and venous cerebrovascular disease. [61, 100]

According to *Seiden et al.* (2004), loss of smell in association with upper respiratory infection is common and has been attributed damage to olfactory epithelial by the causative virus [101]. Anosmia has been reported in up to 30 to 66% of patients and may be an early symptom of infection [102]. Anecdotally, in mild infection, it may be the only clue of infection. Anosmia is often accompanied by ageusia, or loss of taste [102]. Anosmia and ageusia related to COVID-19 typically resolve over several weeks. A high expression of ACE-2 receptor on oral mucosa has been reported and may be related to these symptoms with SARS-CoV-2 [61, 100].

Muscle pain is one of the most common manifestations reported in 35 to 50% of patients [103, 104]. Rhabdomyolysis may occur as a late complication and can result in life-threatening renal impairment [105].

Because of their advanced age and frequent medical comorbidities Vulnerable patients, such as elderly people with cognitive impairment (CI) or dementia, have an increased risk of serious morbidity, admission to intensive care units, and death when infected with COVID-19. Consequently, they have been highly recommended to adhere to social distancing, increasing caregiver burden which might lead patients with cognitive impairment to a faster cognitive deterioration and to worsening of behavioral and psychological symptoms of dementia. It has been suggested that appropriate Telemedicine and Digital Technology approaches can be used to continue providing acceptable standards of care during this pandemic. Follow-up visits, cognitive and digital markers, and effective supporting measurements can be very helpful at the present time. [106] Management of COVID-19 patients should include early clinical, radiologic, and laboratory neurologic assessment, with a close follow-up, especially in severe forms. Future studies should assess late and long-term consequences of current COVID-19 patients with neurologic involvement.

## 5 Conclusion

The COVID-19 pandemic continues to threaten people globally and therefore the global economy due to its potential threat on the healthcare system. Patients with comorbidities are especially more prone to severe complications of COVID-19 and higher rates of hospitalization. Comorbidities may range from any pre-existing cardiac, respiratory, gastrointestinal, endocrine, renal, autoimmune, or other immunocompromised state of a disease. During our literature review we learned about the pathophysiology of SARS-CoV-2 and how it affects multiple organ systems. Currently there is no cure or vaccine for COVID-19 and there is an urgent need to develop targeted therapies as we continue to learn more about this novel virus. Without therapeutic interventions, much of how we contain the viral spread is on prevention through mitigation strategies not limited to social distancing and using face masks and providing supportive care. Symptomatic and supportive care are all clinicians can provide at this time. Early discovery of COVID-19 symptoms with radiological and laboratory assessments may play a major role in preventing the progression to severe disease states of COVID-19.

## 6 Competing Interests

The authors indicate no potential conflicts of interest

## References

- [1] Li, Q., Guan, X., Wu, P., Wang, X., Zhou, L., Tong, Y., ... Feng, Z. (2020). Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. *New England Journal of Medicine*, 382(13), 1199–1207. <https://doi.org/10.1056/nejmoa2001316>
- [2] Kolifarhood, G., Aghaali, M., Mozafar Saadati, H., Taherpour, N., Rahimi, S., Izadi, N., & Hashemi Nazari, S. S. (2020). Epidemiological and Clinical Aspects of COVID-19; a Narrative Review. *Archives of academic emergency medicine*, 8(1), e41.
- [3] The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) — China, 2020[J]. *China CDC Weekly*, 2020, 2(8): 113-122. doi: 10.46234/ccdcw2020.032
- [4] World Health Organization. (2020). *WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020*. World Health Organization. <https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19--11-march-2020>.
- [5] Zu, Z. Y., Jiang, M. D., Xu, P. P., Chen, W., Ni, Q. Q., Lu, G. M., & Zhang, L. J. (2020). *Coronavirus Disease 2019 (COVID-19): A Perspective from China*. *Radiology*, 296(2), E15–E25. <https://doi.org/10.1148/radiol.2020200490>
- [6] Rothan, H. A., & Byrareddy, S. N. (2020). The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. *Journal of autoimmunity*, 109, 102433. <https://doi.org/10.1016/j.jaut.2020.102433>
- [7] Renu K, Prasanna PL, Valsala Gopalakrishnan A. Coronaviruses pathogenesis, comorbidities and multi-organ damage - A review. *Life Sci*. 2020;255:117839. doi:10.1016/j.lfs.2020.117839
- [8] Centers for Disease Control and Prevention. (2020). *COVID-19 Associated Hospitalization Related to Underlying Medical Conditions*. Centers for Disease Control and Prevention. <https://www.cdc.gov/coronavirus/2019-ncov/covid-data/investigations-discovery/hospitalization-underlying-medical-conditions.html>.



- [9] Centers for Disease Control and Prevention. (2020, September 23). *COVID-19 Provisional Counts - Weekly Updates by Select Demographic and Geographic Characteristics*. Centers for Disease Control and Prevention. [https://www.cdc.gov/nchs/nvss/vsrr/covid\\_weekly/index.htm?fbclid=IwAR3-wrg3fTKK5-9tOHPGAHWVFO3DfslkJKsDEPQpWmPbKtp6EsoVV2Qs1Q](https://www.cdc.gov/nchs/nvss/vsrr/covid_weekly/index.htm?fbclid=IwAR3-wrg3fTKK5-9tOHPGAHWVFO3DfslkJKsDEPQpWmPbKtp6EsoVV2Qs1Q).
- [10] World Health Organization. (2020). *Advice for the public on COVID-19*. World Health Organization. <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-public>.
- [11] Berardi, A., Perinelli, D. R., Merchant, H. A., Bisharat, L., Basheti, I. A., Bonacucina, G., ... Palmieri, G. F. (2020). Hand sanitizers amid CoViD-19: A critical review of alcohol-based products on the market and formulation approaches to respond to increasing demand. *International Journal of Pharmaceutics*, 584, 119431. <https://doi.org/10.1016/j.ijpharm.2020.119431>
- [12] Eikenberry, S. E., Mancuso, M., Iboi, E., Phan, T., Eikenberry, K., Kuang, Y., ... Gumel, A. B. (2020). To mask or not to mask: Modeling the potential for face mask use by the general public to curtail the COVID-19 pandemic. *Infectious Disease Modelling*, 5, 293–308. <https://doi.org/10.1016/j.idm.2020.04.001>
- [13] Gandhi, M., Beyrer, C., & Goosby, E. (2020). Masks Do More Than Protect Others During COVID-19: Reducing the Inoculum of SARS-CoV-2 to Protect the Wearer. *Journal of General Internal Medicine*. <https://doi.org/10.1007/s11606-020-06067-8>
- [14] Park, S. W., Sun, K., Viboud, C., Grenfell, B. T., & Dushoff, J. (2020). Potential Role of Social Distancing in Mitigating Spread of Coronavirus Disease, South Korea. *Emerging Infectious Diseases*, 26(11). <https://doi.org/10.3201/eid2611.201099>
- [15] World Health Organization. (2020). *Draft landscape of COVID-19 candidate vaccines*. World Health Organization. <https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines>.
- [16] Zhi, Z. (2020). The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. Retrieved September 14, 2020, from <https://pubmed.ncbi.nlm.nih.gov/32064853/>
- [17] WHO. (2020). Novel Coronavirus (2019-nCoV) Situation Report-1. Retrieved September 14, 2020, from [https://www.who.int/docs/default-source/coronaviruse/situationreports/20200121-sitrep-1-2019-ncov.pdf?sfvrsn=20a99c10\\_4](https://www.who.int/docs/default-source/coronaviruse/situationreports/20200121-sitrep-1-2019-ncov.pdf?sfvrsn=20a99c10_4)
- [18] WHO. (2020). Coronavirus disease 2019 (COVID-19) Situation Report-26. Retrieved September 14, 2020, from [https://www.who.int/docs/default-source/coronaviruse/situationreports/20200215-sitrep-26-covid-19.pdf?sfvrsn=a4cc6787\\_2](https://www.who.int/docs/default-source/coronaviruse/situationreports/20200215-sitrep-26-covid-19.pdf?sfvrsn=a4cc6787_2)
- [19] Holshue, M., Al, E., For the Washington State 2019-nCoV Case Investigation Team\*, Author Affiliations From the Epidemic Intelligence Service (M.L.H.), M. Gandhi and G. W. Rutherford, Ehre, C., & Others, J. (2020, May 07). First Case of 2019 Novel Coronavirus in the United States: NEJM. Retrieved September 15, 2020, from <https://www.nejm.org/doi/full/10.1056/NEJMoa2001191>
- [20] Bashir, M., Ma, B., Bilal, K., Komal, B., Bashir, M., Tan, D., Bashir, M. (August 1st, 2020) Correlation between climate indicators and COVID-19 pandemic in New York, USA. Retrieved 17 sep, 2020 from <https://pubmed.ncbi.nlm.nih.gov/32334162/14.10-13>
- [21] Zimmermann, P., & Curtis, N. (2020, May). Coronavirus Infections in Children Including COVID-19: An Overview of the Epidemiology, Clinical Features, Diagnosis, Treatment and Prevention Options in Children. Retrieved September 15, 2020, from <https://pubmed.ncbi.nlm.nih.gov/32310621/>
- [22] WHO. (2020, September 13). Coronavirus disease (COVID-19) Weekly epidemiological update. Retrieved September 15, 2020, from [https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200914-weekly-epi-update-5.pdf?sfvrsn=cf929d04\\_2](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200914-weekly-epi-update-5.pdf?sfvrsn=cf929d04_2)
- [23] Zhai, P., Ding, Y., Wu, X., Long, J., Jhong, Y., Li, Y. (March, 2020). The epidemiology, diagnosis and treatment of COVID-19. Retrieved 17 Sep, 2020 from <https://pubmed.ncbi.nlm.nih.gov/32234468/>
- [24] Yang, Y., Lu, Q., Liu, M., Wang, Y., Zhang, A., Jalali, N., ... Fang, L. (2020, January 01). Epidemiological and clinical features of the 2019 novel coronavirus outbreak in China. Retrieved September 15, 2020, from <https://www.medrxiv.org/content/10.1101/2020.02.10.20021675v2.abstract>
- [25] The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. (2020, February 01). The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) - China, 2020. Retrieved September 15, 2020, from <http://weekly.chinacdc.cn/en/article/id/e53946e2-c6c4-41e9-9a9b-fea8db1a8f51>
- [26] Zhang, Penninger, Li, Zhong & Slutsky (2020, March 3). Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Retrieved from: <https://rdcu.be/b7OXQ>
- [27] Hu, Y., Sun, J., Dai, Z., et al. Prevalence and severity of corona virus disease 2019 (COVID-19): A systematic review and meta-analysis. *J Clin Viro*. 2020 Jun; 127:104371. Doi:10.1016/j.jcv.2020.10447
- [28] Chu, H., Chan, JF, Wang, Y., Yen TT., et al. Comparative replication and Immune Activation Profile of SARS-CoV-2 and SARS-CoV in Human Lungs: An Ex Vivo Study with implications for the pathogenesis of COVID-19. *Clin Infect Dis*. 2020 Sep 12;71(6):1400-1409. Doi:10.1093/cid/ciaa410. PMID:32270184; PMCID:PMC7184390.
- [29] Ackermann, M., Verleden, S., Kuehnel, M., Haverich, A. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in COVID-19. *N Engl J Med* 2020; 383:120-128. DOI 10.1056/NEJMoa2015432
- [30] Guoping, L., Xiang, H., Zhang, L., Ran, Q. et al. Assessing ACE2 expression patterns in lung tissues in the pathogenesis of COVID-19. *J Autoimmun*. 2020 Aug; 112:102463. Doi 10.1016/j.jaut.2020.102463.
- [31] Li, X., Ma, X. Acute respiratory failure in COVID-19: is it “typical” ARDS? *Crit Care*. 2020; 24: 198. Doi 10.1186/s13054-020-02911-9.
- [32] American Lung Association (2020). What is COVID-19. Retrieved from <https://www.lung.org/lung-health-diseases/lung-disease-lookup/covid-19/about-covid-19> Accessed September 30, 2020.
- [33] Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., Zhang L., Fan G., Xu J., Gu X. Clinical features of patients infected with 2019 novel coronavirus in wuhan, China. *Lancet*. 2020;395:497–506.
- [34] Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. *JAMA*. 2020;323(11):1061–1069. doi:10.1001/jama.2020.1585
- [35] Zhou P., Yang X.-L., Wang X.-G., Hu B., Zhang L., Zhang W., Si H.-R., Zhu Y., Li B., Huang C.-L. Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin. *Nature*. 2020;579:270–273
- [36] World Health Organization (2020). Clinical management of severe acute respiratory infection when novel coronavirus (2019-nCoV) infection is suspected: interim guidance, 28 January 2020. World Health Organization. <https://apps.who.int/irishandle//10665/330893>

- [37] Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. *Nat Rev Cardiol.* 2020 May;17(5):259-260. doi: 10.1038/s41569-020-0360-5. PMID: 32139904; PMCID: PMC7095524.
- [38] Bansal M. Cardiovascular disease and COVID-19. *Diabetes Metab Syndr.* 2020 May-Jun;14(3):247-250. doi: 10.1016/j.dsx.2020.03.013. Epub 2020 Mar 25. PMID: 32247212; PMCID: PMC7102662.
- [39] Kang Y, Chen T, Mui D, Ferrari V, Jagasia D, Scherrer-Crosbie M, Chen Y, Han Y. Cardiovascular manifestations and treatment considerations in COVID-19. *Heart.* 2020 Aug;106(15):1132-1141. doi: 10.1136/heartjnl-2020-317056. Epub 2020 Apr 30. PMID: 32354800; PMCID: PMC7211105.
- [40] Li B, Yang J, Zhao F, Zhi L, Wang X, Liu L, Bi Z, Zhao Y. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. *Clin Res Cardiol.* 2020 May;109(5):531-538. doi: 10.1007/s00392-020-01626-9. Epub 2020 Mar 11. PMID: 32161990; PMCID: PMC7087935.
- [41] Ye, Q., Wang, B., Mao, J. The pathogenesis and treatment of the 'Cytokine Storm' in COVID-19. *J Infect.* 2020 Jun; 80(6): 607–613.
- [42] Sinha, P., Matthay, M., Calfee, C. Is a "Cytokine Storm" relevant to COVID-19? *JAMA Intern Med.* 2020;180(9):1152-1154. doi:10.1001/jamainternmed.2020.3313
- [43] Bhaskar, S., Sinha, A., Banach, M., Mittoo, S., Weissert, R., Kass, J., Rajagopal, S., Pai, A., Kutty, S. Cytokine Storm in COVID-19—Immunopathological Mechanisms, Clinical Considerations, and Therapeutic Approaches: The REPROGRAM Consortium Position Paper. *Front Immunol.* 2020; 11: 1648.
- [44] Mangalmurti, M. & Hunter, C. Cytokine Storms: Understanding COVID-19. *Immunity.* 2020 Jul 14; 53(1): 19–25.
- [45] Sun, X., Wang, T., Cai, D., Hu, Z., Chen, J., Liao, H., Zhi, L., Wei, H., Zhang, Z., Qiu, Y., Wang, J., Cytokine storm intervention in the early stages of COVID-19 pneumonia. *Cytokine Growth Factor Rev.* 2020 Jun; 53: 38–42.
- [46] Matthay MA, Aldrich JM, Gotts JE. Treatment for severe acute respiratory distress syndrome from COVID-19. *Lancet Respir Med* 8: 433–434, 2020. doi:10.1016/S2213-2600(20)30127-2.
- [47] Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, Huang H, Zhang L, Zhou X, Du C, Zhang Y, Song J, Wang S, Chao Y, Yang Z, Xu J, Zhou X, Chen D, Xiong W, Xu L, Zhou F, Jiang J, Bai C, Zheng J, Song Y. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. *AMA Intern Med.* 2020;180(7):934-943. doi:10.1001/jamainternmed.2020.0994. PMID: 32167524, PMCID: PMC7070509
- [48] Battle D, Soler MJ, Sparks MA, Hiremath S, South AM, Welling PA, Swaminathan S; COVID-19 and ACE2 in Cardiovascular, Lung, and Kidney Working Group. Acute Kidney Injury in COVID-19: Emerging Evidence of a Distinct Pathophysiology.
- [49] Husain-Syed et al, F., Slutsky, A. S. & Ronco, C. Lung-kidney cross-talk in the critically ill patient. *Am. J. Respir. Crit. Care Med.* 194, 402–414 (2016)
- [50] Ronco C, Reis T. Kidney involvement in COVID-19 and rationale for extracorporeal therapies. *Nat Rev Nephrol* 2020; 16: 308–310
- [51] Hirsch JS, Ng JH, Ross DW et al. Acute kidney injury in patients hospitalized with COVID-19. *Kidney Int* 2020; 98: 209–218
- [52] Gabarre P, Dumas G, Dupont T, Darmon M, Azoulay E, and Zafrani L. Acute kidney injury in critically ill patients with COVID-19. *Intensive Care Med* 46, 1339–1348 (2020). doi: 10.1007/s00134-020-06153-9. Epub 2020 Jun 12. PMID: 32533197; PMCID: PMC7290076.
- [53] Pei G, Zhang Z, Peng J et al. Renal involvement and early prognosis in patients with COVID-19 pneumonia. *J Am Soc Nephrol.* 2020 Jun; 31(6):1157-1165. doi: 10.1681/ASN.2020030276. Epub 2020 Apr 28. PMID: 32345702; PMCID: PMC7269350.
- [54] Ishigami J, Matsushita K. Clinical epidemiology of infectious disease among patients with chronic kidney disease. *Clin Exp Nephrol* 23: 437–447, 2019.
- [55] Chia Siang Kow and Syed Shahzad Hasan. *JASN* August 2020, 31 (8) 1917-1918; DOI: <https://doi.org/10.1681/ASN.2020050640>
- [56] Ronco C, Reis T, Husain-Syed F. Management of acute kidney injury in patients with COVID-19. *Lancet Respir Med.* 2020 Jul; 8(7): 738–742. Published online 2020 May 14. doi: 10.1016/S2213-2600(20)30229-0. PMID: 32416769; PMCID: PMC7255232.
- [57] Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B. et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. *JAMA.* 2020;323(11):1061–1069. doi: 10.1001/jama.2020.1585
- [58] Burgner A, Ikizler TA, Dwyer JP. COVID-19 and the Inpatient Dialysis Unit. *Clin J Am Soc Nephrol.* April 2020:CJN.03750320. doi:10.2215/CJN.03750320
- [59] Tadic, M., Cuspidi, C., & Sala, C. (2020). COVID-19 and diabetes: Is there enough evidence?. *Journal of clinical hypertension (Greenwich, Conn.)*, 22(6), 943–948. <https://doi.org/10.1111/jch.13912>
- [60] Lian, J., Jin, X., Hao, S., Cai, H., Zhang, S., Zheng, L., Jia, H., Hu, J., Gao, J., Zhang, Y., Zhang, X., Yu, G., Wang, X., Gu, J., Ye, C., Jin, C., Lu, Y., Yu, X., Yu, X., Ren, Y., ... Yang, Y. (2020). Analysis of Epidemiological and Clinical Features in Older Patients With Coronavirus Disease 2019 (COVID-19) Outside Wuhan. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*, 71(15), 740–747. <https://doi.org/10.1093/cid/ciaa242>
- [61] Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N. H., Nitsche, A., Müller, M. A., Drosten, C., & Pöhlmann, S. (2020). SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell*, 181(2), 271–280.e8. <https://doi.org/10.1016/j.cell.2020.02.052>
- [62] Fang, L., Karakiulakis, G., & Roth, M. (2020). Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?. *The Lancet. Respiratory medicine*, 8(4), e21. [https://doi.org/10.1016/S2213-2600\(20\)30116-8](https://doi.org/10.1016/S2213-2600(20)30116-8)
- [63] Guo, W., Li, M., Dong, Y., Zhou, H., Zhang, Z., Tian, C., Qin, R., Wang, H., Shen, Y., Du, K., Zhao, L., Fan, H., Luo, S., & Hu, D. (2020). Diabetes is a risk factor for the progression and prognosis of COVID-19. *Diabetes/metabolism research and reviews*, e3319. Advance online publication. <https://doi.org/10.1002/dmrr.3319>
- [64] Patel, K. P., Patel, P. A., Vunnam, R. R., Hewlett, A. T., Jain, R., Jing, R., & Vunnam, S. R. (2020). Gastrointestinal, hepatobiliary, and pancreatic manifestations of COVID-19. *Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology*, 128, 104386. <https://doi.org/10.1016/j.jcv.2020.104386>
- [65] Wang, F., Wang, H., Fan, J., Zhang, Y., Wang, H., & Zhao, Q. (2020). Pancreatic Injury Patterns in Patients With Coronavirus Disease 19 Pneumonia. *Gastroenterology*, 159(1), 367–370. <https://doi.org/10.1053/j.gastro.2020.03.055>

- [66] Muniyappa & Gubbi (2020, April 26). COVID-19 pandemic, coronaviruses, and diabetes mellitus: American Journal of Physiology, endocrinology and metabolism. Retrieved from: <<https://doi.org/10.1152/ajpendo.00124.2020>>
- [67] Kumar, A., Arora, A., Sharma, P., Anikhindi, S. A., Bansal, N., Singla, V., Khare, S., & Srivastava, A. (2020). Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis. *Diabetes & metabolic syndrome*, 14(4), 535–545. <https://doi.org/10.1016/j.dsx.2020.04.044>
- [68] Singh, A. K., Gupta, R., Ghosh, A., & Misra, A. (2020). Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations. *Diabetes & metabolic syndrome*, 14(4), 303–310. <https://doi.org/10.1016/j.dsx.2020.04.004>
- [69] Gu, J., Han, B., & Wang, J. (2020). COVID-19: Gastrointestinal Manifestations and Potential Fecal-Oral Transmission. *Gastroenterology*, 158(6), 1518–1519. <https://doi.org/10.1053/j.gastro.2020.02.054>
- [70] Cheong, J., Bartell, N., Peeraphatdit, T., Mosli, M., & Al-Judaibi, B. (2020). Gastrointestinal and liver manifestations of COVID-19. *Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association*, 26(5), 226–232. [https://doi.org/10.4103/sjg.SJG\\_147\\_20](https://doi.org/10.4103/sjg.SJG_147_20)
- [71] Cha, M. H., Regueiro, M., & Sandhu, D. S. (2020). Gastrointestinal and hepatic manifestations of COVID-19: A comprehensive review. *World journal of gastroenterology*, 26(19), 2323–2332. <https://doi.org/10.3748/wjg.v26.i19.2323>
- [72] Baryah, A., Midha, V., Mahajan, R., & Sood, A. (2020). Impact of Corona Virus Disease-19 (COVID-19) pandemic on gastrointestinal disorders. *Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology*, 39(3), 214–219. <https://doi.org/10.1007/s12664-020-01071-6>
- [73] Kotfis, K., & Skonieczna-Zydecka, K. (2020). COVID-19: gastrointestinal symptoms and potential sources of SARS-CoV-2 transmission. *Anaesthesiology intensive therapy*, 52(2), 171–172. <https://doi.org/10.5114/ait.2020.93867>
- [74] Téllez L, Martín Mateos RM. COVID-19 and liver disease: An update. *Gastroenterologia y hepatologia*. 2020.
- [75] Cai Q, Huang D, Ou P, Yu H, Zhu Z, Xia Z, et al. COVID-19 in a designated infectious diseases hospital outside Hubei Province, China. *Allergy*. 2020.
- [76] Fan Z, Chen L, Li J, Cheng X, Yang J, Tian C, et al. Clinical features of COVID-19-related liver damage. *Clinical Gastroenterology and Hepatology*. 2020.
- [77] Guan W-j, Ni Z-y, Hu Y, Liang W-h, Ou C-q, He J-x, et al. Clinical characteristics of coronavirus disease 2019 in China. *New England journal of medicine*. 2020;382(18):1708-20.
- [78] Li L, Li S, Xu M, Yu P, Zheng S, Duan Z, et al. Risk factors related to hepatic injury in patients with corona virus disease 2019. *medRxiv*. 2020.
- [79] Liu W, Tao Z-W, Wang L, Yuan M-L, Liu K, Zhou L, et al. Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. *Chinese medical journal*. 2020.
- [80] Shi H, Han X, Jiang N, Cao Y, Alwalid O, Gu J, et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. *The Lancet Infectious Diseases*. 2020.
- [81] Wu J, Li W, Shi X, Chen Z, Jiang B, Liu J, et al. Early antiviral treatment contributes to alleviate the severity and improve the prognosis of patients with novel coronavirus disease (COVID-19). *Journal of internal medicine*. 2020.
- [82] Zhang Y, Zheng L, Liu L, Zhao M, Xiao J, Zhao Q. Liver impairment in COVID-19 patients: A retrospective analysis of 115 cases from a single centre in Wuhan city, China. *Liver International*. 2020.
- [83] Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. *The Lancet respiratory medicine*. 2020;8(4):420-2.
- [84] Chau TN, Lee KC, Yao H, Tsang TY, Chow TC, Yeung YC, et al. SARS-associated viral hepatitis caused by a novel coronavirus: report of three cases. *Hepatology*. 2004;39(2):302-10.
- [85] Moiseev S, Avdeev S, Brovko M, et al Rheumatic diseases in intensive care unit patients with COVID-19. *Annals of the Rheumatic Diseases* Published Online First: 20 May 2020. doi: 10.1136/annrheumdis-2020-217676
- [86] Scirè CA, Carrara G, Zanetti A, Landolfi G, Chighizola C, Alunno A, Andreoli L, Caporali R, Gerli R, Sebastiani GD, Valesini G, Sinigaglia L; Italian Registry of the Italian Society for Rheumatology (CONTROL-19). COVID-19 in rheumatic diseases in Italy: first results from the Italian registry of the Italian Society for Rheumatology (CONTROL-19). *Clin Exp Rheumatol*. 2020 Jul-Aug;38(4):748-753. Epub 2020 Jul 28. PMID: 32723435.
- [87] Friedman, N. et al. Human coronavirus infections in Israel: epidemiology, clinical symptoms and summer seasonality of HCoV-HKU1. *Viruses* 10, 515 (2018).
- [88] Christian, M. D., Poutanen, S. M., Loutfy, M. R., Muller, M. P. & Low, D. E. Severe acute respiratory syndrome. *Clin. Infect. Dis.* 38, 1420–1427 (2004).
- [89] Li, S. et al. Symptom combinations associated with outcome and therapeutic effects in a cohort of cases with SARS. *Am. J. Chin. Med.* 34, 937–947 (2006).
- [90] Schett, G., Manger, B., Simon, D. et al. COVID-19 revisiting inflammatory pathways of arthritis. *Nat Rev Rheumatol* 16, 465–470 (2020). <https://doi.org/10.1038/s41584-020-0451-z>
- [91] Mikuls R, Johnson SR, Fraenkel L, Arasaratnam RJ, Baden LR, Bermas BL, et al. (2020) American College of Rheumatology Guidance for the management of adult patients with rheumatic disease during the COVID-19 pandemic. *Arthritis Rheumatol* (Hoboken, NJ)
- [92] Favalli E.G., Biggioggero M., Meroni P.L. Methotrexate for the treatment of rheumatoid arthritis in the biologic era: still an “anchor” drug? *Autoimmun Rev*. 2014;13:1102–1108. doi: 10.1016/j.autrev.2014.08.026
- [93] Favalli E.G., Raimondo M.G., Becciolini A., Crotti C., Biggioggero M., Caporali R. The management of first-line biologic therapy failures in rheumatoid arthritis: current practice and future perspectives. *Autoimmun Rev*. 2017;16:1185–1195. doi: 10.1016/j.autrev.2017.10.002.
- [94] Mark A Ellul et al (2020) Neurological associations of Covid-19. *Lancet Neurol* 2020; 19: 767–83 [https://doi.org/10.1016/S1474-4422\(20\)30221-0](https://doi.org/10.1016/S1474-4422(20)30221-0)
- [95] Olds J.L., Kabbani N. Is nicotine exposure linked to cardiopulmonary vulnerability to COVID-19 in the general population? *FEBS J*. 2020 n/a(n/a).

- [96] McFadden G. Cytokine determinants of viral tropism. *Nat. Rev. Immunol.* 2009;9(9):645–655.
- [97] Zhou L, Zhang M, Gao J, Wang J. Sars-Cov-2: underestimated damage to nervous system. *Travel Med Infect Dis.* 2020;101642.-
- [98] Berger J. R. (2020). COVID-19 and the nervous system. *Journal of neurovirology*, 26(2), 143–148. <https://doi.org/10.1007/s13365-020-00840-5>
- [99] Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. (2020) Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet*
- [100] Xu H, Zhong L, Deng J, Peng J, Dan H, Zeng X et al (2020) High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. *Int J Oral Sci.* 12(1):8
- [101] Seiden AM. Postviral olfactory loss. *Otolaryngol Clin N Am.* 2004;37(6):1159–1166. doi: 10.1016/j.otc.2004.06.007.
- [102] Hopkins C, Kumar N (2020) Loss of sense of smell as a marker of COVID-19 infection. ENTUK [cited 2020 March 30]; Available from: <https://www.entuk.org/sites/default/files/files/Loss%20of%20sense%20of%20smell%20as%20marker%20of%20COVID.pdf>
- [103] Xu XW, Wu XX, Jiang XG, Xu KJ, Ying LJ, Ma CL, Li SB, Wang HY, Zhang S, Gao HN, Sheng JF, Cai HL, Qiu YQ, Li LJ Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. *BMJ.* 2020 Feb 19; 368():m606.
- [104] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet.* 2020 Feb 15; 395(10223):497-506.
- [105] He, Y., & Chen, F. (2020). Rhabdomyolysis as Potential Late Complication Associated with COVID-19. *Emerging Infectious Diseases*, 26(9), 2297-2298. <https://dx.doi.org/10.3201/eid2609.201463>.
- [106] Cuffaro, L., Di Lorenzo, F., Bonavita, S., Tedeschi, G., Leocani, L., & Lavorgna, L. (2020). Dementia care and COVID-19 pandemic: a necessary digital revolution. *Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology*, 41(8), 1977–1979. <https://doi.org/10.1007/s10072-020-04512-4>